- Home
- MIRM vs HTGC Comparison
MIRM vs HTGC Comparison
Compare MIRM & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- HTGC
- Stock Information
- Founded
- MIRM 2018
- HTGC 2003
- Country
- MIRM United States
- HTGC United States
- Employees
- MIRM N/A
- HTGC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- HTGC Investment Managers
- Sector
- MIRM Health Care
- HTGC Finance
- Exchange
- MIRM Nasdaq
- HTGC Nasdaq
- Market Cap
- MIRM 3.7B
- HTGC 3.2B
- IPO Year
- MIRM 2019
- HTGC 2005
- Fundamental
- Price
- MIRM $70.45
- HTGC $17.48
- Analyst Decision
- MIRM Strong Buy
- HTGC Buy
- Analyst Count
- MIRM 11
- HTGC 8
- Target Price
- MIRM $82.82
- HTGC $21.13
- AVG Volume (30 Days)
- MIRM 596.2K
- HTGC 1.3M
- Earning Date
- MIRM 11-04-2025
- HTGC 10-30-2025
- Dividend Yield
- MIRM N/A
- HTGC 10.87%
- EPS Growth
- MIRM N/A
- HTGC N/A
- EPS
- MIRM N/A
- HTGC 1.75
- Revenue
- MIRM $471,794,000.00
- HTGC $516,847,000.00
- Revenue This Year
- MIRM $53.14
- HTGC $8.72
- Revenue Next Year
- MIRM $19.83
- HTGC $9.57
- P/E Ratio
- MIRM N/A
- HTGC $9.87
- Revenue Growth
- MIRM 53.66
- HTGC 4.54
- 52 Week Low
- MIRM $36.88
- HTGC $15.65
- 52 Week High
- MIRM $78.55
- HTGC $22.04
- Technical
- Relative Strength Index (RSI)
- MIRM 50.06
- HTGC 45.03
- Support Level
- MIRM $68.60
- HTGC $16.97
- Resistance Level
- MIRM $73.02
- HTGC $17.67
- Average True Range (ATR)
- MIRM 3.10
- HTGC 0.31
- MACD
- MIRM 0.08
- HTGC -0.02
- Stochastic Oscillator
- MIRM 54.27
- HTGC 44.86
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.